Clinical Trial Update: Characterization of the Serotonin 2A Receptor Selective PET Tracer [18F]MH.MZ in Patients With Neurodegenerative Diseases [Phase 4]

View source ↗

Summary

Phase 4 trial update describing the PET tracer [18F]MH.MZ for imaging serotonin 2A receptors in Parkinson's disease and Parkinson's disease psychosis, with ongo…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Parkinson Disease
• Parkinson Disease Psychosis

Drugs mentioned

• [18F]MH.MZ

Snippet

Sponsor: Vanderbilt University Medical Center | Conditions: Neurodegenerative Diseases, Parkinson Disease | Phase 4 | Status: RECRUITING